Age and Dose Are Major Risk Factors for Liver Damage Associated with Intravenous Glucocorticoid Pulse Therapy for Graves' Orbitopathy

被引:32
|
作者
Sisti, Eleonora [1 ,2 ]
Coco, Barbara [3 ]
Menconi, Francesca [1 ,2 ]
Leo, Marenza [1 ,2 ]
Rocchi, Roberto [1 ,2 ]
Latrofa, Francesco [1 ,2 ]
Profilo, Maria Antonietta [1 ,2 ]
Mazzi, Barbara [1 ,2 ]
Vitti, Paolo [1 ,2 ]
Marcocci, Claudio [1 ,2 ]
Brunetto, Maurizia [3 ]
Marino, Michele [1 ,2 ]
机构
[1] Univ Pisa, Dept Clin & Expt Med, Endocrinol Units, I-56124 Pisa, Italy
[2] Univ Hosp Pisa, I-56124 Pisa, Italy
[3] Univ Hosp Pisa, Hepatol Unit, Pisa, Italy
关键词
AUTOIMMUNE HEPATITIS; METHYLPREDNISOLONE; OPHTHALMOPATHY; MANAGEMENT; PATIENT; DISEASE;
D O I
10.1089/thy.2015.0061
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: High-dose intravenous glucocorticoid (ivGC) pulse therapy, which is commonly used for Graves' orbitopathy (GO), has been associated with acute liver damage (ALD), resulting in a fatal outcome in a few cases. No certain risk factors for ALD have been established. Consequently, a large retrospective cohort study was performed. Methods: The relationship between ALD and several potential risk factors was assessed in 1076 consecutive patients with GO given ivGC. ALD was defined as an increase of alanine aminotransferase 300IU/L. Results: Fourteen cases of ALD were recorded, resulting in a morbidity of 1.3%. Thirteen patients recovered and one died, resulting in a mortality of 0.09%. There was a significant, positive correlation of ALD with age and methylprednisolone acetate (MPA) cumulative dose, and ALD was more common (relative risk [RR]=2.8; p=0.05) in patients aged 53 years (9/420; 2.14%) than in those aged <53 years (5/656; 0.76%). In patients aged 53 years, there was a significant positive correlation of ALD with MPA cumulative dose, and with MPA dose per infusion. Thus, the frequency of ALD in this age group was greater (RR=3.48; p=0.04) in patients with a MPA dose per infusion 0.7g (5/111, 4.5% vs. 4/308, 1.29%). Regardless of age, no cases of ALD were observed for MPA doses per infusion <0.57g. Conclusions: Age and MPA dose are significant risk factors for ALD, with the following practical implications. First, the total MPA cumulative dose should not exceed 8.5g (the average dose in patients without ALD). Second, in patients aged 53 years, selection and observation should be quite strict. However, being aged 53 years should not be seen as an absolute contraindication to ivGC, especially in patients with severe GO, considering that the risk of ALD, although statistically significant, was relatively low. Third, the MPA dose should not exceed 0.57g per infusion, a measure to be applied regardless of age.
引用
收藏
页码:846 / 850
页数:5
相关论文
共 50 条
  • [21] High-Dose Intravenous Glucocorticoid Therapy for Graves' Ophthalmopathy: Where Are We Now?
    Bahn, Rebecca
    THYROID, 2012, 22 (01) : 1 - 2
  • [22] TREATMENT OF GRAVES OPHTHALMOPATHY WITH HIGH-DOSE INTRAVENOUS METHYLPREDNISOLONE PULSE THERAPY
    NAGAYAMA, Y
    IZUMI, M
    KIRIYAMA, T
    YOKOYAMA, N
    MORITA, S
    KAKEZONO, F
    OHTAKARA, S
    MORIMOTO, I
    OKAMOTO, S
    NAGATAKI, S
    ACTA ENDOCRINOLOGICA, 1987, 116 (04): : 513 - 518
  • [23] Sex-specific risk factors associated with graves' orbitopathy in Korean patients with newly diagnosed graves' disease
    Lee, Jooyoung
    Kang, Jinmo
    Ahn, Hwa Young
    Lee, Jeong Kyu
    EYE, 2023, 37 (16) : 3382 - 3391
  • [24] Sex-specific risk factors associated with graves’ orbitopathy in Korean patients with newly diagnosed graves’ disease
    Jooyoung Lee
    Jinmo Kang
    Hwa Young Ahn
    Jeong Kyu Lee
    Eye, 2023, 37 : 3382 - 3391
  • [25] High-dose intravenous pulse therapy with methylprednisolone and orbital irradiation in graves' ophthalmopathy
    Vaisman, M
    Violane, AHD
    Conceiçao, FL
    Soares, DV
    Buescu, A
    ENDOCRINOLOGIST, 2001, 11 (01): : 53 - 56
  • [26] Autoimmune hepatitis during intravenous glucocorticoid pulse therapy for Graves’ ophthalmopathy treated successfully with glucocorticoids themselves
    M. Marinò
    E. Morabito
    M. A. Altea
    E. Ambrogini
    F. Oliveri
    M. R. Brunetto
    L. E. Pollina
    D. Campani
    P. Vitti
    L. Bartalena
    A. Pinchera
    C. Marcocci
    Journal of Endocrinological Investigation, 2005, 28 : 280 - 284
  • [27] Autoimmune hepatitis during intravenous glucocorticoid pulse therapy for Graves' ophthalmopathy treated successfully with glucocorticoids themselves
    Marinò, M
    Morabito, E
    Altea, MA
    Ambrogini, E
    Oliveri, F
    Brunetto, MR
    Pollina, LE
    Campani, D
    Vitti, P
    Bartalena, L
    Pinchera, A
    Marcocci, C
    JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 2005, 28 (03) : 280 - 284
  • [28] Therapy of moderate-to-severe Graves’ orbitopathy with intravenous methylprednisolone pulses is not associated with loss of bone mineral density
    Joanna Rymuza
    Michał Popow
    Zuzanna Żurecka
    Jerzy Przedlacki
    Tomasz Bednarczuk
    Piotr Miśkiewicz
    Endocrine, 2019, 64 : 308 - 315
  • [29] Therapy of moderate-to-severe Graves' orbitopathy with intravenous methylprednisolone pulses is not associated with loss of bone mineral density
    Rymuza, Joanna
    Popow, Michal
    Zurecka, Zuzanna
    Przedlacki, Jerzy
    Bednarczuk, Tomasz
    Miskiewicz, Piotr
    ENDOCRINE, 2019, 64 (02) : 308 - 315
  • [30] Glucocorticoid-induced adrenal insufficiency after therapy with intravenous methylprednisolone in patients with moderate-to-severe and active Graves' orbitopathy: assessment with a low-dose corticotropin test
    Pelewicz, K.
    Miskiewicz, P.
    JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 2024, 47 (08) : 1987 - 1994